Morgan Stanley’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $227K | Sell |
25,698
-17,622
| -41% | -$156K | ﹤0.01% | 5801 |
|
|
2025
Q1 | $466K | Sell |
43,320
-17,394
| -29% | -$187K | ﹤0.01% | 5360 |
|
|
2024
Q4 | $777K | Sell |
60,714
-25,681
| -30% | -$329K | ﹤0.01% | 5216 |
|
|
2024
Q3 | $2.38M | Buy |
86,395
+63,857
| +283% | +$1.76M | ﹤0.01% | 4519 |
|
|
2024
Q2 | $654K | Sell |
22,538
-4,730
| -17% | -$137K | ﹤0.01% | 5171 |
|
|
2024
Q1 | $1.22M | Sell |
27,268
-27,492
| -50% | -$1.23M | ﹤0.01% | 4861 |
|
|
2023
Q4 | $2.12M | Buy |
54,760
+42,013
| +330% | +$1.63M | ﹤0.01% | 4889 |
|
|
2023
Q3 | $375K | Sell |
12,747
-4,829
| -27% | -$142K | ﹤0.01% | 5301 |
|
|
2023
Q2 | $1.12M | Buy |
17,576
+5,292
| +43% | +$337K | ﹤0.01% | 4769 |
|
|
2023
Q1 | $580K | Buy |
12,284
+1,340
| +12% | +$63.2K | ﹤0.01% | 5168 |
|
|
2022
Q4 | $760K | Sell |
10,944
-9,810
| -47% | -$681K | ﹤0.01% | 5017 |
|
|
2022
Q3 | $3.04M | Buy |
20,754
+9,909
| +91% | +$1.45M | ﹤0.01% | 4102 |
|
|
2022
Q2 | $1.42M | Sell |
10,845
-7,057
| -39% | -$921K | ﹤0.01% | 4774 |
|
|
2022
Q1 | $1.81M | Sell |
17,902
-32,185
| -64% | -$3.25M | ﹤0.01% | 4589 |
|
|
2021
Q4 | $7.75M | Buy |
50,087
+23,137
| +86% | +$3.58M | ﹤0.01% | 3231 |
|
|
2021
Q3 | $7.98M | Sell |
26,950
-55,392
| -67% | -$16.4M | ﹤0.01% | 3164 |
|
|
2021
Q2 | $26.7M | Buy |
+82,342
| New | +$26.7M | ﹤0.01% | 1852 |
|